News

Ahead of American Heart Month, USA Today talks with Dr. James O’Keefe of the Saint Luke’s Mid America Heart Institute about five steps you can take to reduce your risk of developing heart disease.

According to a new study, higher omega-3 levels significantly reduce the risk of heart failure and heart failure fatalities.

A potassium binder helped patients with heart failure who have or are at high risk for hyperkalemia stay on spironolactone at an optimal dose, but showed a signal of HF hospitalization risk.

A secondary analysis of the pooled STEP-HFpEF and STEP-HFpEF DM trials showed the greatest improvements in those with the most weight loss at 52 weeks.

BBC News talked to Dr. Mikhail Kosiborod about new findings on the cardiovascular effects of semaglutide.

A new subanalysis presented by Dr. Mikhail Kosiborod shows benefits of semaglutide in patients with atrial fibrillation.

On average, survival benefits of CPR for cardiac arrest could be three times as high for white adults compared to Black adults and twice as high for men compared to women.

Semaglutide improves symptoms in both men and women who present with heart failure. When it comes to weight loss, however, the drug appears to benefit women much more than men.

Consumer Reports On Health talked to Dr. Bethany Austin and Austin Workman about strategies to improve quality of life for those living with heart failure.

The popular weight loss drug Wegovy seems to provide more health benefits for people who have diabetes and a common kind of heart failure than just helping take off the pounds, according to the results from the STEP HFpEF DM trial.